| CPC A61B 5/027 (2013.01) [A61B 5/0275 (2013.01); A61B 5/4848 (2013.01); A61B 18/1492 (2013.01); A61B 2018/00404 (2013.01); A61B 2018/00434 (2013.01); A61B 2018/00511 (2013.01); A61B 2018/00577 (2013.01); A61B 2018/00642 (2013.01); A61B 2018/00863 (2013.01); A61B 2018/00875 (2013.01); A61B 2018/0212 (2013.01); A61B 2018/1435 (2013.01); A61B 2018/167 (2013.01)] | 20 Claims | 

| 
               1. A method comprising: 
            positioning a catheter including one or more electrodes at a target site within a blood vessel of a patient; 
                delivering neuromodulation energy at the target site via at least one electrode of the one or more electrodes of the catheter; 
                introducing a bolus of an indicator fluid into the blood vessel upstream of the target site relative to a direction of blood flow in the blood vessel, the bolus having a known volume; 
                obtaining a measurement related to a blood flow rate through the blood vessel via the catheter, wherein obtaining the measurement related to the blood flow rate includes: 
                determining a transient change in an impedance in the blood vessel resulting from the bolus of the indicator fluid; 
                  determining the measurement related to the blood flow rate based on the transient change in the impedance and the known volume; and 
                  correcting the measurement related to the blood flow rate for at least one of a current leakage into surrounding tissue of the blood vessel or a non-homogeneity of an impedance field across a cross-sectional area of the blood vessel, wherein correcting the measurement is based on a flow rate offset and a flow rate gain term; 
                comparing the measurement to a baseline measurement related to the blood flow rate through the blood vessel; and 
                assessing efficacy of neuromodulation therapy based, at least in part, on the comparison. 
               |